CA2998911C - Administration of deuterated cftr potentiators - Google Patents
Administration of deuterated cftr potentiators Download PDFInfo
- Publication number
- CA2998911C CA2998911C CA2998911A CA2998911A CA2998911C CA 2998911 C CA2998911 C CA 2998911C CA 2998911 A CA2998911 A CA 2998911A CA 2998911 A CA2998911 A CA 2998911A CA 2998911 C CA2998911 C CA 2998911C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- ivacaftor
- ctp
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562221531P | 2015-09-21 | 2015-09-21 | |
| US62/221,531 | 2015-09-21 | ||
| US201562238511P | 2015-10-07 | 2015-10-07 | |
| US62/238,511 | 2015-10-07 | ||
| US201662348855P | 2016-06-10 | 2016-06-10 | |
| US62/348,855 | 2016-06-10 | ||
| PCT/US2016/052922 WO2017053455A1 (en) | 2015-09-21 | 2016-09-21 | Administration of deuterated cftr potentiators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2998911A1 CA2998911A1 (en) | 2017-03-30 |
| CA2998911C true CA2998911C (en) | 2023-05-23 |
Family
ID=58387264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2998911A Active CA2998911C (en) | 2015-09-21 | 2016-09-21 | Administration of deuterated cftr potentiators |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20180353500A1 (https=) |
| EP (2) | EP3352757B1 (https=) |
| JP (2) | JP6849686B2 (https=) |
| KR (1) | KR102828163B1 (https=) |
| CN (1) | CN108367002A (https=) |
| AU (2) | AU2016326441B2 (https=) |
| BR (1) | BR112018005454A2 (https=) |
| CA (1) | CA2998911C (https=) |
| HK (1) | HK1258472A1 (https=) |
| IL (2) | IL257993A (https=) |
| MA (1) | MA42950A (https=) |
| MX (1) | MX388470B (https=) |
| RU (1) | RU2761344C2 (https=) |
| SG (1) | SG10201913588YA (https=) |
| UA (1) | UA124619C2 (https=) |
| WO (1) | WO2017053455A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| MA41051B1 (fr) | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose |
| EP3277647A1 (en) | 2015-03-31 | 2018-02-07 | Vertex Pharmaceuticals (Europe) Limited | Deuterated vx-661 |
| KR102828163B1 (ko) | 2015-09-21 | 2025-07-02 | 버텍스 파마슈티칼스 (유럽) 리미티드 | 중수소화된 cftr 강화제의 투여 |
| EP3352758A2 (en) | 2015-09-25 | 2018-08-01 | Vertex Pharmaceuticals (Europe) Limited | Deuterated cftr potentiators |
| CA3019380A1 (en) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN109803962B (zh) | 2016-09-30 | 2022-04-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物 |
| MD3551622T2 (ro) | 2016-12-09 | 2021-03-31 | Vertex Pharma | Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului |
| US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US20200171015A1 (en) * | 2017-07-17 | 2020-06-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| JP7121794B2 (ja) | 2017-08-02 | 2022-08-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピロリジン化合物を調製するためのプロセス |
| WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
| MA51206A (fr) | 2017-12-01 | 2020-10-07 | Vertex Pharma | Procédés pour préparer des modulateurs de régulateur de conductance transmembranaire de mucoviscidose |
| EP3720849A2 (en) | 2017-12-08 | 2020-10-14 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| JP7214743B2 (ja) | 2018-02-15 | 2023-01-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法 |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| EA202191361A1 (ru) | 2018-11-14 | 2021-08-11 | Вертекс Фармасьютикалз Инкорпорейтед | Способы лечения муковисцидоза |
| UY38630A (es) | 2019-04-03 | 2020-10-30 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
| FR3096890B1 (fr) | 2019-06-07 | 2021-05-14 | H4 Orphan Pharma | Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique. |
| US20220313698A1 (en) | 2019-08-14 | 2022-10-06 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2021030552A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| FR3109524B1 (fr) | 2020-04-22 | 2022-04-08 | H4 Orphan Pharma | Utilisation d’un ligand multifonctionnel pour traiter l’œil sec et les dysfonctionnements des glandes de Meibomius et des glandes lacrymales. |
| FR3111071B1 (fr) | 2020-06-04 | 2023-01-13 | H4 Orphan Pharma | Utilisation de ligands multifonctionnels pour traiter les syndromes de détresse respiratoire et le choc cytokinique liés aux infections virales à coronavirus. |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| IL300413A (en) | 2020-08-13 | 2023-04-01 | Vertex Pharma | Crystal forms of CFTR modulators |
| WO2022076622A2 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| KR20230104618A (ko) | 2020-10-07 | 2023-07-10 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막관통 전도도 조절자의 조절제 |
| EP4225446A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225737A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076626A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| AU2021356651A1 (en) | 2020-10-07 | 2023-05-18 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230373974A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230373935A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225762A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| KR20230118123A (ko) | 2020-12-10 | 2023-08-10 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 치료 방법 |
| JP2025506382A (ja) | 2022-02-03 | 2025-03-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症の治療方法 |
| JP2025505643A (ja) | 2022-02-08 | 2025-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子の調節因子 |
| CA3258118A1 (en) | 2022-04-06 | 2023-10-12 | Vertex Pharmaceuticals Incorporated | MODULATORS OF THE TRANSMEMBRANE CONDUCTANCE REGULATOR IN CYSTIC FIBROSIS |
| WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2025076240A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025166342A1 (en) | 2024-02-04 | 2025-08-07 | Vertex Pharmaceuticals Incorporated | Combination of vanzacaftor, tezacaftor, deutivacaftor for use in treating cystic fibrosis |
| EP4648753B1 (en) | 2024-02-07 | 2026-02-18 | Vertex Pharmaceuticals Incorporated | Compositions for the treatment of cftr-mediated diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| HU229938B1 (en) | 2001-05-03 | 2015-01-28 | Hoffmann La Roche | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
| US20060094744A1 (en) | 2004-09-29 | 2006-05-04 | Maryanoff Cynthia A | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| EP3219705B1 (en) | 2005-12-28 | 2020-03-11 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| MX2011001782A (es) | 2008-08-13 | 2012-02-08 | Vertex Pharma | Composicion farmaceutica y su administracion. |
| AU2011255237A1 (en) | 2010-05-20 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| RS56096B1 (sr) * | 2011-05-18 | 2017-10-31 | Concert Pharmaceuticals Inc | Deuterisani derivati ivakaftora |
| JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| MY183582A (en) * | 2012-11-19 | 2021-02-26 | Vertex Pharmaceuticals Europe Ltd | Deuterated cftr potentiators |
| CN103833630B (zh) * | 2012-11-21 | 2018-11-13 | 顶点制药（欧洲）有限公司 | 氘化cftr增效剂 |
| US20140221424A1 (en) * | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
| KR102828163B1 (ko) | 2015-09-21 | 2025-07-02 | 버텍스 파마슈티칼스 (유럽) 리미티드 | 중수소화된 cftr 강화제의 투여 |
-
2016
- 2016-09-21 KR KR1020187010964A patent/KR102828163B1/ko active Active
- 2016-09-21 HK HK19100788.5A patent/HK1258472A1/zh unknown
- 2016-09-21 RU RU2018114447A patent/RU2761344C2/ru active
- 2016-09-21 UA UAA201804280A patent/UA124619C2/uk unknown
- 2016-09-21 BR BR112018005454A patent/BR112018005454A2/pt not_active Application Discontinuation
- 2016-09-21 MA MA042950A patent/MA42950A/fr unknown
- 2016-09-21 WO PCT/US2016/052922 patent/WO2017053455A1/en not_active Ceased
- 2016-09-21 AU AU2016326441A patent/AU2016326441B2/en active Active
- 2016-09-21 US US15/761,532 patent/US20180353500A1/en not_active Abandoned
- 2016-09-21 SG SG10201913588YA patent/SG10201913588YA/en unknown
- 2016-09-21 JP JP2018534496A patent/JP6849686B2/ja active Active
- 2016-09-21 EP EP16849524.0A patent/EP3352757B1/en active Active
- 2016-09-21 CN CN201680067707.1A patent/CN108367002A/zh active Pending
- 2016-09-21 EP EP23191452.4A patent/EP4292588A3/en active Pending
- 2016-09-21 CA CA2998911A patent/CA2998911C/en active Active
- 2016-09-21 MX MX2018003331A patent/MX388470B/es unknown
-
2018
- 2018-03-08 IL IL257993A patent/IL257993A/en unknown
-
2020
- 2020-05-14 US US15/931,944 patent/US20200375973A1/en active Pending
-
2021
- 2021-03-04 JP JP2021034591A patent/JP7196217B2/ja active Active
-
2022
- 2022-02-21 AU AU2022201135A patent/AU2022201135B2/en active Active
- 2022-03-20 IL IL291517A patent/IL291517A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022201135B2 (en) | Administration of deuterated cftr potentiators | |
| AU2017352206B2 (en) | Methods of treatment with deuterated CFTR potentiators | |
| US20210052570A1 (en) | Methods of treatment with deuterated cftr potentiators | |
| US20240423986A1 (en) | Treatment of hair loss disorders with deuterated jak inhibitors | |
| US20150315152A2 (en) | Pharmaceutical Compositions for the Treatment of CFTR-Mediated Disorders | |
| AU2016243171A1 (en) | Deuterated VX-661 | |
| AU2011242454A1 (en) | Pharmaceutical compositions and administrations thereof | |
| IL302401A (en) | Regimens for the treatment of hair loss disorders with faded JAC inhibitors | |
| HK40102764A (en) | Administration of deuterated cftr potentiators | |
| OA19045A (en) | Administration of deuterated CFTR potentiators. | |
| US20250275977A1 (en) | Dosage regimens for treatment with deuterated jak inhibitors | |
| AU2017217806A1 (en) | Deuterium-modified CFTR modulators | |
| HK40112813A (en) | Treatment of hair loss disorders with deuterated jak inhibitors | |
| EA052710B1 (ru) | Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210920 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240913 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240913 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240913 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250912 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250916 |